Over 20 years have passed since the first RNA-based drug was approved by FDA, and now several RNA drugs have been approved for therapeutic applications in different diseases, including TTR-mediated amyloidosis, duchenne muscular dystrophy, hypercholesterolemia, etc. Additionally, hundreds of candidate drugs are currently under clinical studies. The gene discussed is TTR; the disease is amyloidosis.